Panel: Modalities and markets at the crossroads - Where advanced therapies go next and how Europe chooses to compete

The next modality frontier is not guaranteed: Which modalities are genuinely emerging as the next growth engines, whether cell therapies face structural headwinds or reinvention, and what lessons Europe should take from genomics, RNA and adjacent fields that have already lived through hype cycles.

Competition is no longer just scientific: How macro forces such as trade policy, capital mobility, industrial strategy and regional risk tolerance are shaping where advanced therapies are developed, manufactured and commercialised heading into 2027.

US, China, Middle East: different bets, different rules: What each region is truly optimising for, speed, cost, control, talent or scale, where they are strongest, and how realistic collaboration or co-development actually is for European companies.

The grey market risk Europe cannot ignore: How sub-standard stem cell products and loosely regulated therapies emerging in some markets could distort patient trust, pricing and standards globally, and what responsibility Europe has in setting and defending quality benchmarks.

Compete, collaborate, or draw lines: As other regions push aggressively on cost and speed, how Europe should think about manufacturing strategy, supply chain resilience and risk boundaries, and where cooperation strengthens Europe versus where it weakens it.